Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2 Trial of IPH2201 And Cetuximab in Patients With Human Papillomavirus (HPV) (+) and HPV (-) Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT02643550 is registered in ClinicalTrials.gov with Innate Pharma as lead sponsor.

NCT NCT02643550
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02643550 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2 Trial of IPH2201 And Cetuximab in Patients With Human Papillomavirus (HPV) (+) and HPV (-) Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
Innate Pharma
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2015
Completion date
March 28, 2023
Enrollment
143 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck neoplasms